Lack of therapeutic improvement of liver fibrosis in rats by dexamethasone in spite of ascites amelioration

Sung Hwan Ki, DalWoong Choi, Choon Won Kim, Sang Geon Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pathophysiology of liver fibrosis (LF) includes hepatic parenchymal cell destruction and connective tissue formation. Although dexamethasone has been used in the liver diseases, there is controversy over the beneficial effects of dexamethasone on LF. Previous studies showed that CCAAT/enhancer binding protein-β (C/EBPβ) activation contributes to hepatocyte regeneration and dissolution of fibrosis and that dexamethasone activates C/EBPβ whereas C/EBPβ-mediated gene induction by dexamethasone is antagonized by a corepressor. The present study investigated the possible therapeutic effect of dexamethasone for the treatment of LF in rats. We injected rats with multiple doses of dimethylnitrosamine (DMN) for 4 weeks and then used the LF rats to determine whether dexamethasone treatment therapeutically improved liver functions and resolved fibers accumulated in the liver. Dexamethasone (100 μg/kg, po, three times per week for 4 weeks) failed to restore the body weight gain and liver weight decreased by LF. The body weight gain reduced during LF was further decreased by dexamethasone treatment. Animals were subjected to blood biochemical, liver histopathological and immunochemical analyses. Although dexamethasone treatment significantly reduced ascites in LF rats, the plasma albumin and total protein levels decreased in fibrotic rats were not restored. Impaired liver functions during LF including elevated plasma aminotransferases and bilirubin levels along with GSTA2 repression were not recovered by dexamethasone. Dexamethasone failed to decrease the fibrosis score and to eliminate the extracellular matrix and α-smooth muscle actin accumulated in the fibrotic liver. The results of the present study showed that dexamethasone ameliorated ascites in LF rats but failed to improve the liver functions and fiber accumulation, and that the possible beneficial effect of dexamethasone might result from anti-inflammatory effect but not from liver improvement.

Original languageEnglish
Pages (from-to)37-47
Number of pages11
JournalChemico-Biological Interactions
Volume152
Issue number1
DOIs
Publication statusPublished - 2005 Feb 28
Externally publishedYes

Fingerprint

Ascites
Liver Cirrhosis
Liver
Dexamethasone
Rats
CCAAT-Enhancer-Binding Proteins
Therapeutics
Weight Gain
Hepatocytes
Fibrosis
Body Weight
Dimethylnitrosamine
Co-Repressor Proteins
Therapeutic Uses
Transaminases
Bilirubin
Serum Albumin
Connective Tissue
Extracellular Matrix
Smooth Muscle

Keywords

  • α-SMA
  • Dexamethasone
  • Liver fibrosis
  • Liver function

ASJC Scopus subject areas

  • Toxicology

Cite this

Lack of therapeutic improvement of liver fibrosis in rats by dexamethasone in spite of ascites amelioration. / Ki, Sung Hwan; Choi, DalWoong; Kim, Choon Won; Kim, Sang Geon.

In: Chemico-Biological Interactions, Vol. 152, No. 1, 28.02.2005, p. 37-47.

Research output: Contribution to journalArticle

@article{762483ec14594d549c1bfa2bfbfc9660,
title = "Lack of therapeutic improvement of liver fibrosis in rats by dexamethasone in spite of ascites amelioration",
abstract = "Pathophysiology of liver fibrosis (LF) includes hepatic parenchymal cell destruction and connective tissue formation. Although dexamethasone has been used in the liver diseases, there is controversy over the beneficial effects of dexamethasone on LF. Previous studies showed that CCAAT/enhancer binding protein-β (C/EBPβ) activation contributes to hepatocyte regeneration and dissolution of fibrosis and that dexamethasone activates C/EBPβ whereas C/EBPβ-mediated gene induction by dexamethasone is antagonized by a corepressor. The present study investigated the possible therapeutic effect of dexamethasone for the treatment of LF in rats. We injected rats with multiple doses of dimethylnitrosamine (DMN) for 4 weeks and then used the LF rats to determine whether dexamethasone treatment therapeutically improved liver functions and resolved fibers accumulated in the liver. Dexamethasone (100 μg/kg, po, three times per week for 4 weeks) failed to restore the body weight gain and liver weight decreased by LF. The body weight gain reduced during LF was further decreased by dexamethasone treatment. Animals were subjected to blood biochemical, liver histopathological and immunochemical analyses. Although dexamethasone treatment significantly reduced ascites in LF rats, the plasma albumin and total protein levels decreased in fibrotic rats were not restored. Impaired liver functions during LF including elevated plasma aminotransferases and bilirubin levels along with GSTA2 repression were not recovered by dexamethasone. Dexamethasone failed to decrease the fibrosis score and to eliminate the extracellular matrix and α-smooth muscle actin accumulated in the fibrotic liver. The results of the present study showed that dexamethasone ameliorated ascites in LF rats but failed to improve the liver functions and fiber accumulation, and that the possible beneficial effect of dexamethasone might result from anti-inflammatory effect but not from liver improvement.",
keywords = "α-SMA, Dexamethasone, Liver fibrosis, Liver function",
author = "Ki, {Sung Hwan} and DalWoong Choi and Kim, {Choon Won} and Kim, {Sang Geon}",
year = "2005",
month = "2",
day = "28",
doi = "10.1016/j.cbi.2005.01.008",
language = "English",
volume = "152",
pages = "37--47",
journal = "Chemico-Biological Interactions",
issn = "0009-2797",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Lack of therapeutic improvement of liver fibrosis in rats by dexamethasone in spite of ascites amelioration

AU - Ki, Sung Hwan

AU - Choi, DalWoong

AU - Kim, Choon Won

AU - Kim, Sang Geon

PY - 2005/2/28

Y1 - 2005/2/28

N2 - Pathophysiology of liver fibrosis (LF) includes hepatic parenchymal cell destruction and connective tissue formation. Although dexamethasone has been used in the liver diseases, there is controversy over the beneficial effects of dexamethasone on LF. Previous studies showed that CCAAT/enhancer binding protein-β (C/EBPβ) activation contributes to hepatocyte regeneration and dissolution of fibrosis and that dexamethasone activates C/EBPβ whereas C/EBPβ-mediated gene induction by dexamethasone is antagonized by a corepressor. The present study investigated the possible therapeutic effect of dexamethasone for the treatment of LF in rats. We injected rats with multiple doses of dimethylnitrosamine (DMN) for 4 weeks and then used the LF rats to determine whether dexamethasone treatment therapeutically improved liver functions and resolved fibers accumulated in the liver. Dexamethasone (100 μg/kg, po, three times per week for 4 weeks) failed to restore the body weight gain and liver weight decreased by LF. The body weight gain reduced during LF was further decreased by dexamethasone treatment. Animals were subjected to blood biochemical, liver histopathological and immunochemical analyses. Although dexamethasone treatment significantly reduced ascites in LF rats, the plasma albumin and total protein levels decreased in fibrotic rats were not restored. Impaired liver functions during LF including elevated plasma aminotransferases and bilirubin levels along with GSTA2 repression were not recovered by dexamethasone. Dexamethasone failed to decrease the fibrosis score and to eliminate the extracellular matrix and α-smooth muscle actin accumulated in the fibrotic liver. The results of the present study showed that dexamethasone ameliorated ascites in LF rats but failed to improve the liver functions and fiber accumulation, and that the possible beneficial effect of dexamethasone might result from anti-inflammatory effect but not from liver improvement.

AB - Pathophysiology of liver fibrosis (LF) includes hepatic parenchymal cell destruction and connective tissue formation. Although dexamethasone has been used in the liver diseases, there is controversy over the beneficial effects of dexamethasone on LF. Previous studies showed that CCAAT/enhancer binding protein-β (C/EBPβ) activation contributes to hepatocyte regeneration and dissolution of fibrosis and that dexamethasone activates C/EBPβ whereas C/EBPβ-mediated gene induction by dexamethasone is antagonized by a corepressor. The present study investigated the possible therapeutic effect of dexamethasone for the treatment of LF in rats. We injected rats with multiple doses of dimethylnitrosamine (DMN) for 4 weeks and then used the LF rats to determine whether dexamethasone treatment therapeutically improved liver functions and resolved fibers accumulated in the liver. Dexamethasone (100 μg/kg, po, three times per week for 4 weeks) failed to restore the body weight gain and liver weight decreased by LF. The body weight gain reduced during LF was further decreased by dexamethasone treatment. Animals were subjected to blood biochemical, liver histopathological and immunochemical analyses. Although dexamethasone treatment significantly reduced ascites in LF rats, the plasma albumin and total protein levels decreased in fibrotic rats were not restored. Impaired liver functions during LF including elevated plasma aminotransferases and bilirubin levels along with GSTA2 repression were not recovered by dexamethasone. Dexamethasone failed to decrease the fibrosis score and to eliminate the extracellular matrix and α-smooth muscle actin accumulated in the fibrotic liver. The results of the present study showed that dexamethasone ameliorated ascites in LF rats but failed to improve the liver functions and fiber accumulation, and that the possible beneficial effect of dexamethasone might result from anti-inflammatory effect but not from liver improvement.

KW - α-SMA

KW - Dexamethasone

KW - Liver fibrosis

KW - Liver function

UR - http://www.scopus.com/inward/record.url?scp=17644375164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644375164&partnerID=8YFLogxK

U2 - 10.1016/j.cbi.2005.01.008

DO - 10.1016/j.cbi.2005.01.008

M3 - Article

VL - 152

SP - 37

EP - 47

JO - Chemico-Biological Interactions

JF - Chemico-Biological Interactions

SN - 0009-2797

IS - 1

ER -